Management of Chronic Lymphocytic Leukemia

The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.

Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.

Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.

Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.

At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.

Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.

The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.

LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.